Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
No holdings reported for quarter Q4 2023 |
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
Kalvista Pharmaceuticals | 6 | Q4 2019 | 21.5% |
Obseva SA | 6 | Q4 2019 | 15.8% |
Constellation Pharmaceuticals | 6 | Q4 2019 | 23.5% |
Marinus Pharmaceuticals Inc | 6 | Q4 2019 | 5.1% |
Bellerophon Therapeutics | 6 | Q4 2019 | 1.9% |
BioCryst Pharmaceuticals Inc | 5 | Q3 2019 | 18.0% |
Tricida Inc | 5 | Q3 2019 | 15.0% |
Protagonist Therapeutics Inc | 5 | Q4 2019 | 8.0% |
Kiniksa Pharmaceuticals Ltd | 5 | Q3 2019 | 6.7% |
Axsome Therapeutics Inc | 4 | Q4 2019 | 31.8% |
View VHCP Management III, LLC's complete holdings history.
Latest filings
Type | Filed |
---|---|
4 | 2024-02-22 |
4 | 2024-02-08 |
4 | 2024-02-01 |
4 | 2024-01-29 |
4 | 2024-01-24 |
4 | 2024-01-19 |
4 | 2024-01-16 |
4 | 2024-01-10 |
4 | 2024-01-05 |
4 | 2023-12-29 |
View VHCP Management III, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.